Współczesne Metody Identyfikacji Białkowych Antygenów Szczepionkowych
References
- Altschul S.F., Gish W., Miller W., Myers E.W., Lipman D.J.: Basic local alignment search tool. <em>J Mol Biol</em>, <bold>215</bold>, 403–410 (1990)
- Bairoch A., Apweiler R., Wu C.H., Barker W.C., Boeckmann B., Ferro S., Gasteiger E., Huang H., Lopez R., Magrane M. <em>et al.</em>: The Universal Protein Resource (UniProt). <em>Nucleic Acids Res</em>, <bold>33</bold>, D154–159 (2005)
- Biagini M., Spinsanti M., De Angelis G., Tomei S., Ferlenghi I., Scarselli M., Rigat F., Messuti N., Biolchi A., Muzzi A. <em>et al.</em>: Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined. <em>Proc Natl Acad Sci USA</em>, <bold>113</bold>, 2714–2719 (2016)
- Bidmos F.A., Nadel S., Screaton G.R., Kroll J.S., Langford P.R.: Cross-Reactive Bactericidal Antimeningococcal Antibodies Can Be Isolated From Convalescing Invasive Meningococcal Disease Patients Using Reverse Vaccinology 2.0. <em>Front Immunol</em>, <bold>9</bold>, 1621 (2018)
- Bidmos F.A., Siris S., Gladstone C.A., Langford P.R.: Bacterial Vaccine Antigen Discovery in the Reverse Vaccinology 2.0 Era: Progress and Challenges. <em>Front Immunol</em>, <bold>9</bold>, 2315 (2018)
- Burton D.R.: Advancing an HIV vaccine; advancing vaccinology. <em>Nat Rev Immunol</em>, <bold>19</bold>, 77–78 (2019)
- Bylsma L.C., Suh M., Movva N., Fryzek J.P., Nelson C.B.: Mortality Among US Infants and Children Under 5 Years of Age with Respiratory Syncytial Virus and Bronchiolitis: A Systematic Literature Review. <em>J Infect Dis</em>, <bold>226</bold>, S267–S281 (2022)
- Christensen H., May M., Bowen L., Hickman M., Trotter C.L.: Meningococcal carriage by age: a systematic review and meta-analysis. <em>Lancet Infect Dis</em>, <bold>10</bold>, 853–861 (2010)
- Close B.E., Wilkinson J.M., Bohrer T.J., Goodwin C.P., Broom L.J., Colley K.J.: The polysialyltransferase ST8Sia II/STX: posttranslational processing and role of autopolysialylation in the polysialylation of neural cell adhesion molecule. <em>Glycobiology</em>, <bold>11</bold>, 997–1008 (2001)
- Collins P.L., Melero J.A.: Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. <em>Virus Res</em>, <bold>162</bold>, 80–99 (2011)
- Ding C., Ma J., Dong Q., Liu Q.: Live bacterial vaccine vector and delivery strategies of heterologous antigen: A review. <em>Immunol Lett</em>, <bold>197</bold>, 70–77 (2018)
- Durrheim D.N.: Measles eradication-retreating is not an option. <em>Lancet Infect Dis</em>, <bold>20</bold>, e138–e141 (2020)
- Elveborg S., Monteil V.M., Mirazimi A.: Methods of Inactivation of Highly Pathogenic Viruses for Molecular, Serology or Vaccine Development Purposes. <em>Pathogens</em>, <bold>11</bold>, (2022)
- Emms D.M., Kelly S.: OrthoFinder: solving fundamental biases in whole genome comparisons dramatically improves orthogroup inference accuracy. <em>Genome Biol</em>, <bold>16</bold>, 157 (2015)
- Fagnocchi L., Biolchi A., Ferlicca F., Boccadifuoco G., Brunelli B., Brier S., Norais N., Chiarot E., Bensi G., Kroll J.S. <em>et al.</em>: Transcriptional regulation of the nadA gene in Neisseria meningitidis impacts the prediction of coverage of a multicomponent meningococcal serogroup B vaccine. <em>Infect Immun</em>, <bold>81</bold>, 560–569 (2013)
- Gandhi A., Balmer P., York L.J.: Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba(R)). <em>Postgrad Med</em>, <bold>128</bold>, 548–556 (2016)
- Gilman M.S., Castellanos C.A., Chen M., Ngwuta J.O., Goodwin E., Moin S.M., Mas V., Melero J.A., Wright P.F., Graham B.S. <em>et al.</em>: Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. <em>Sci Immunol</em>, <bold>1</bold>, (2016)
- Henderson D.A.: The eradication of smallpox-an overview of the past, present, and future. <em>Vaccine</em>, <bold>29</bold>, D7–9 (2011)
- Holst J., Oster P., Arnold R., Tatley M.V., Naess L.M., Aaberge I.S., Galloway Y., McNicholas A., O’Hallahan J., Rosenqvist E. <em>et al.</em>: Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. <em>Hum Vaccin Immunother</em>, <bold>9</bold>, 1241–1253 (2013)
- First-in-human clinical trial confirms novel HIV vaccine approach developed by IAVI and Scripps Research (<a href="https://www.iavi.org/news-resources/press-releases/2021/first-in-human-clinical-trial-confirms-novel-hiv-vaccine-approach-developed-by-iavi-and-scripps-research" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://www.iavi.org/news-resources/press-releases/2021/first-in-human-clinical-trial-confirms-novel-hiv-vaccine-approach-developed-by-iavi-and-scripps-research</a>) (2021)
- Johswich K.: Innate immune recognition and inflammation in <em>Neisseria meningitidis</em> infection. <em>Pathog Dis</em>, <bold>75</bold>, (2017)
- Kennedy D.A., Read A.F.: Why the evolution of vaccine resistance is less of a concern than the evolution of drug resistance. <em>Proc Natl Acad Sci USA</em>, <bold>115</bold>, 12878–12886 (2018)
- Kim H., Webster R.G., Webby R.J.: Influenza Virus: Dealing with a Drifting and Shifting Pathogen. <em>Viral Immunol</em>, <bold>31</bold>, 174–183 (2018)
- Klugman K.P., Black S.: Impact of existing vaccines in reducing antibiotic resistance: Primary and secondary effects. <em>Proc Natl Acad Sci USA</em>, <bold>115</bold>, 12896–12901 (2018)
- Lauring A.S., Jones J.O., Andino R.: Rationalizing the development of live attenuated virus vaccines. <em>Nat Biotechnol</em>, <bold>28</bold>, 573–579 (2010)
- Le Basle Y., Chennell P., Tokhadze N., Astier A., Sautou V.: Phsicochemical Stability of Monoclonal Antibodies: A Review. <em>J Pharm Sci</em>, <bold>109</bold>, 169–190 (2020)
- Liao H.X., Lynch R., Zhou T., Gao F., Alam S.M., Boyd S.D., Fire A.Z., Roskin K.M., Schramm C.A., Zhang Z. <em>et al.</em>: Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. <em>Nature</em>, <bold>496</bold>, 469–476 (2013)
- Liguori A., Dello Iacono L., Maruggi G., Benucci B., Merola M., Lo Surdo P., Lopez-Sagaseta J., Pizza M., Malito E., Bottomley M.J.: NadA3 Structures Reveal Undecad Coiled Coils and LOX1 Binding Regions Competed by Meningococcus B Vaccine-Elicited Human Antibodies. <em>MBio</em>, <bold>9</bold>, (2018)
- Liljeroos L., Krzyzaniak M.A., Helenius A., Butcher S.J.: Architecture of respiratory syncytial virus revealed by electron cryotomography. <em>Proc Natl Acad Sci USA</em>, <bold>110</bold>, 11133–11138 (2013)
- Liu B., Zheng D., Zhou S., Chen L., Yang J.: VFDB 2022: a general classification scheme for bacterial virulence factors. <em>Nucleic Acids Res</em>, <bold>50</bold>, D912–D917 (2022)
- Lu D.R., Tan Y.C., Kongpachith S., Cai X., Stein E.A., Lindstrom T.M., Sokolove J., Robinson W.H.: Identifying functional anti-<em>Staphylococcus aureus</em> antibodies by sequencing antibody repertoires of patient plasmablasts. <em>Clin Immunol</em>, <bold>152</bold>, 77–89 (2014)
- Luo H., Lin Y., Gao F., Zhang C.T., Zhang R.: DEG 10, an update of the database of essential genes that includes both protein-coding genes and noncoding genomic elements. <em>Nucleic Acids Res</em>, <bold>42</bold>, D574–580 (2014)
- Martinson J.N.V., Walk S.T.: <em>Escherichia coli</em> Residency in the Gut of Healthy Human Adults. <em>EcoSal Plus</em>, <bold>9</bold>, (2020)
- Masignani V., Pizza M., Moxon E.R.: The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology. <em>Front Immunol</em>, <bold>10</bold>, 751 (2019)
- Mastrangelo P., Hegele R.G.: RSV fusion: time for a new model. <em>Viruses</em>, <bold>5</bold>, 873–885 (2013)
- McAleer W.J., Buynak E.B., Maigetter R.Z., Wampler D.E., Miller W.J., Hilleman M.R.: Human hepatitis B vaccine from recombinant yeast. <em>Nature</em>, <bold>307</bold>, 178–180 (1984)
- McArthur A.G., Waglechner N., Nizam F., Yan A., Azad M.A., Baylay A.J., Bhullar K., Canova M.J., De Pascale G., Ejim L. <em>et al</em>: The comprehensive antibiotic resistance database. <em>Antimicrob Agents Chemother</em>, <bold>57</bold>, 3348–3357 (2013)
- McLellan J.S., Chen M., Joyce M.G., Sastry M., Stewart-Jones G.B., Yang Y., Zhang B., Chen L., Srivatsan S., Zheng A. <em>et al.</em>: Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. <em>Science</em>, <bold>342</bold>, 592–598 (2013)
- McLellan J.S., Chen M., Leung S., Graepel K.W., Du X., Yang Y., Zhou T., Baxa U., Yasuda E., Beaumont T. <em>et al.</em>: Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. <em>Science</em>, <bold>340</bold>, 1113–1117 (2013)
- McLellan J.S., Ray W.C., Peeples M.E.: Structure and function of respiratory syncytial virus surface glycoproteins. <em>Curr Top Microbiol Immunol</em>, <bold>372</bold>, 83–104 (2013)
- Medini D., Donati C., Tettelin H., Masignani V., Rappuoli R.: The microbial pangenome. <em>Curr Opin Genet Dev</em>, <bold>15</bold>, 589–594 (2005)
- Morales M., Tangermann R.H., Wassilak S.G.: Progress Toward Polio Eradication – Worldwide, 2015–2016. <em>MMWR Morb Mortal Wkly Rep</em>, <bold>65</bold>, 470–473 (2016)
- Moxon E.R.: Applications of molecular microbiology to vaccinology. <em>Lancet</em>, <bold>350</bold>, 1240–1244 (1997)
- Mukhamedova M., Wrapp D., Shen C.H., Gilman M.S.A., Ruckwardt T.J., Schramm C.A., Ault L., Chang L., Derrien-Colemyn A., Lucas S.A.M. <em>et al.</em>: Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. <em>Immunity</em>, <bold>54</bold>, 769–780 e766 (2021)
- Naz K., Naz A., Ashraf S.T., Rizwan M., Ahmad J., Baumbach J., Ali A.: PanRV: Pangenome-reverse vaccinology approach for identifications of potential vaccine candidates in microbial pangenome. <em>BMC Bioinformatics</em>, <bold>20</bold>, 123 (2019)
- Nesta B., Pizza M.: Vaccines Against Escherichia coli. <em>Curr Top Microbiol Immunol</em>, <bold>416</bold>, 213–242 (2018)
- O’Hagan D.T., Lodaya R.N., Lofano G.: The continued advance of vaccine adjuvants – ‘we can work it out’. <em>Semin Immunol</em>, <bold>50</bold>, 101426 (2020)
- Omersel J., Karas Kuzelicki N.: Vaccinomics and Adversomics in the Era of Precision Medicine: A Review Based on HBV, MMR, HPV, and COVID-19 Vaccines. <em>J Clin Med</em>, <bold>9</bold>, (2020)
- Osterloh A.: Vaccination against Bacterial Infections: Challenges, Progress, and New Approaches with a Focus on Intracellular Bacteria. <em>Vaccines</em> (<em>Basel</em>), <bold>10</bold>, (2022)
- Poland G.A., Kennedy R.B., McKinney B.A., Ovsyannikova I.G., Lambert N.D., Jacobson R.M., Oberg A.L.: Vaccinomics, adversomics, and the immune response network theory: individualized vaccinology in the 21st century. <em>Semin Immunol</em>, <bold>25</bold>, 89–103 (2013)
- Poland G.A., Ovsyannikova I.G., Jacobson R.M.: Personalized vaccines: the emerging field of vaccinomics. <em>Expert Opin Biol Ther</em>, <bold>8</bold>, 1659–1667 (2008)
- Poland G.A., Ovsyannikova I.G., Jacobson R.M.: Adversomics: the emerging field of vaccine adverse event immunogenetics. <em>Pediatr Infect Dis J</em>, <bold>28</bold>, 431–432 (2009)
- Pulendran B., P S.A., O’Hagan D.T.: Emerging concepts in the science of vaccine adjuvants. <em>Nat Rev Drug Discov</em>, <bold>20</bold>, 454–475 (2021)
- Rappuoli R.: Reverse vaccinology. <em>Curr Opin Microbiol</em>, <bold>3</bold>, 445–450 (2000)
- Rappuoli R., Bottomley M.J., D’Oro U., Finco O., De Gregorio E.:Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. <em>J Exp Med</em>, <bold>213</bold>, 469–481 (2016)
- Rodrigues C.M.C., Plotkin S.A.: Impact of Vaccines; Health, Economic and Social Perspectives. <em>Front Microbiol</em>, <bold>11</bold>, 1526 (2020)
- Scarselli M., Giuliani M.M., Adu-Bobie J., Pizza M., Rappuoli R.: The impact of genomics on vaccine design. <em>Trends Biotechnol</em>, <bold>23</bold>, 84–91 (2005)
- Schneider M.C., Prosser B.E., Caesar J.J., Kugelberg E., Li S., Zhang Q., Quoraishi S., Lovett J.E., Deane J.E., Sim R.B. <em>et al.</em>: <em>Neisseria meningitidis</em> recruits factor H using protein mimicry of host carbohydrates. <em>Nature</em>, <bold>458</bold>, 890–893 (2009)
- Serruto D., Spadafina T., Ciucchi L., Lewis L.A., Ram S., Tontini M., Santini L., Biolchi A., Seib K.L., Giuliani M.M. <em>et al.</em>: <em>Neisseria meningitidis</em> GNA2132, a heparin-binding protein that induces protective immunity in humans. <em>Proc Natl Acad Sci USA</em>, <bold>107</bold>, 3770–3775 (2010)
- Shaw C.A., Ciarlet M., Cooper B.W., Dionigi L., Keith P., O’Brien K.B., Rafie-Kolpin M., Dormitzer P.R.: The path to an RSV vaccine. <em>Curr Opin Virol</em>, <bold>3</bold>, 332–342 (2013)
- Shi S., Zhu H., Xia X., Liang Z., Ma X., Sun B.: Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity. <em>Vaccine</em>, <bold>37</bold>, 3167–3178 (2019)
- Siris S.: Identification of pneumococcal vaccine antigens using Reverse Vaccinology 2.0. <em>Thesis or dissertation.</em> London: Imperial College London; 2021.
- Spadiut O., Capone S., Krainer F., Glieder A., Herwig C.: Microbials for the production of monoclonal antibodies and antibody fragments. <em>Trends Biotechnol</em>, <bold>32</bold>, 54–60 (2014)
- Stephens D.S., Greenwood B., Brandtzaeg P.: Epidemic meningitis, meningococcaemia, and <em>Neisseria meningitidis</em>. <em>Lancet</em>, <bold>369</bold>, 2196–2210 (2007)
- Tatusov R.L., Koonin E.V., Lipman D.J.: A genomic perspective on protein families. <em>Science</em>, <bold>278</bold>, 631–637 (1997)
- Tettelin H., Masignani V., Cieslewicz M.J., Donati C., Medini D., Ward N.L., Angiuoli S.V., Crabtree J., Jones A.L., Durkin A.S. <em>et al.</em>: Genome analysis of multiple pathogenic isolates of <em>Streptococcus agalactiae:</em> implications for the microbial “pangenome”. <em>Proc Natl Acad Sci USA</em>, <bold>102</bold>, 13950–13955 (2005)
- The: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. <em>Pediatrics</em>, <bold>102</bold>, 531–537 (1998)
- Thwaites C.L., Loan H.T.: Eradication of tetanus. <em>Br Med Bull</em>, <bold>116</bold>, 69–77 (2015)
- Tong L., Huang S., Zheng C., Zhang Y., Chen Z.: Refractory <em>Mycoplasma pneumoniae</em> Pneumonia in Children: Early Recognition and Management. <em>J Clin Med</em>, <bold>11</bold> (2022)
- van de Berg D., Kis Z., Behmer C.F., Samnuan K., Blakney A.K., Kontoravdi C., Shattock R., Shah N.: Quality by design modelling to support rapid RNA vaccine production against emerging infectious diseases. <em>NPJ Vaccines</em>, <bold>6</bold>, 65 (2021)
- Vilela Rodrigues T.C., Jaiswal A.K., de Sarom A., de Castro Oliveira L., Freire Oliveira C.J., Ghosh P., Tiwari S., Miranda F.M., de Jesus Benevides L., Ariston de Carvalho Azevedo V. <em>et al.</em>: Reverse vaccinology and subtractive genomics reveal new therapeutic targets against <em>Mycoplasma pneumoniae</em>: a causative agent of pneumonia. <em>R Soc Open Sci</em>, <bold>6</bold>, 190907 (2019)
- Whitaker J.A., Ovsyannikova I.G., Poland G.A.: Adversomics: a new paradigm for vaccine safety and design. <em>Expert Rev Vaccines</em>, <bold>14</bold>, 935–947 (2015)
- Wu X., Zhang Z., Schramm C.A., Joyce M.G., Kwon Y.D., Zhou T., Sheng Z., Zhang B., O’Dell S., McKee K. <em>et al.</em>: Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection. <em>Cell</em>, <bold>161</bold>, 470–485 (2015)
- Yao L., Sun T.: Glycyrrhizin administration ameliorates Streptococcus aureus-induced acute lung injury. <em>Int Immunopharmacol</em>, <bold>70</bold>, 504–511 (2019)
- Yokoyama W.M., Christensen M., Santos G.D., Miller D., Ho J., Wu T., Dziegelewski M., Neethling F.A.: Production of monoclonal antibodies. <em>Curr Protoc Immunol</em>, <bold>102</bold>, 251–2529 (2013)
- Zhou C.E., Smith J., Lam M., Zemla A., Dyer M.D., Slezak T.: MvirDB--a microbial database of protein toxins, virulence factors and antibiotic resistance genes for bio-defence applications. <em>Nucleic Acids Res</em>, <bold>35</bold>, D391–394 (2007)
- Zhou T., Georgiev I., Wu X., Yang Z.Y., Dai K., Finzi A., Kwon Y.D., Scheid J.F., Shi W., Xu L. <em>et al.</em>: Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. <em>Science</em>, <bold>329</bold>, 811–817 (2010)
Language: English, Polish
Page range: 211 - 221
Submitted on: Oct 1, 2022
Accepted on: Nov 1, 2022
Published on: Nov 30, 2022
Published by: Polish Society of Microbiologists
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2022 Rafał Jabłuszewski, Agnieszka Wyszyńska, published by Polish Society of Microbiologists
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.